What is Krystal Biotech, Inc.'s revenue?

Krystal Biotech, Inc. (KRYS) generated $417.3M in revenue over the trailing twelve months, up 25.1% year over year.

Is Krystal Biotech, Inc. profitable?

Krystal Biotech, Inc. reported $225.0M in net income over the trailing twelve months, a 53.9% net margin.

What is Krystal Biotech, Inc.'s earnings per share?

Krystal Biotech, Inc.'s diluted EPS over the trailing twelve months is $7.48.

Where does Krystal Biotech, Inc.'s income statement data come from?

Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Krystal Biotech, Inc. KRYS Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$389.13M+33.9%	$290.51M+473%	$50.7M—	——
Research and development	$58.05M+8.3%	$53.58M+15.4%	$46.43M+9.4%	$42.46M+52.3%
Selling, general and administrative	$146.83M+29.2%	$113.64M+15.6%	$98.29M—	——
Other operating expenses	$227.93M+1.4%	$224.79M+40.2%	$160.32M+10.4%	$145.2M+113%
Total operating expenses	$227.93M+1.4%	$224.79M+40.2%	$160.32M+10.4%	$145.2M+113%
Operating income	$161.2M+145%	$65.73M+158%	-$112.86M+22.3%	-$145.2M-113%
Operating margin	41.4%+18.8pp	22.6%+245pp	-222.6%—	——
Interest expense	$28.27M-4.6%	$29.63M—	——	$0-100%
Income before income taxes	$189.47M+98.7%	$95.36M—	——	-$139.98M-101%
Income tax expense	-$15.36M-348%	$6.2M+215%	$1.97M—	$0—
Net income	$204.83M+130%	$89.16M+716%	$10.93M+108%	-$139.98M-101%
Net margin	52.6%+21.9pp	30.7%+9.1pp	21.6%—	——
Diluted earnings per share	$6.85+128%	$3.00+3,233%	$0.09+102%	-$5.51-76.0%
Basic earnings per share	$7.08+128%	$3.11+1,537%	$0.19+103%	-$5.51-76.0%
Weighted-average shares, diluted	119.4M+0.7%	118.6M+8.8%	109M+7.1%	101.8M+15.8%
Weighted-average shares, basic	115.6M+1.2%	114.2M+6.2%	107.6M+5.7%	101.8M+15.8%
Cost of goods sold	$23.05M+14.9%	$20.06M+548%	$3.09M—	——
Legal contingency and settlement	$0+100%	-$37.5M-200%	-$12.5M—	——
Interest Income (Expense), Nonoperating	$28.27M-4.6%	$29.63M—	——	$5.22M—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$206.16M+133%	$88.33M+618%	$12.3M+109%	-$140.54M-102%
Depreciation	$5.67M-3.7%	$5.89M+17.4%	$5.02M+89.8%	$2.64M+42.9%
Net unrealized gains (losses) on securities still held	——	-$440K-131%	$1.43M—	——
Revenue From Contract With Customer Excluding Assessed Tax	$389.13M+33.9%	$290.51M+473%	$50.7M—	——
EBIT	$161.2M+145%	$65.73M+158%	-$112.86M+22.3%	-$145.2M-113%
EBITDA	$166.88M+133%	$71.62M+166%	-$108.77M+22.9%	-$141.14M-115%
EBITDA	$166.88M+133%	$71.62M+166%	-$108.77M+22.9%	-$141.14M-115%
EBITDA margin	42.9%+18.2pp	24.7%+239pp	-214.5%—	——
EBIT	$161.2M+145%	$65.73M+158%	-$112.86M+22.3%	-$145.2M-113%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Krystal Biotech, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Krystal Biotech, Inc.'s revenue?: Krystal Biotech, Inc. (KRYS) generated $417.3M in revenue over the trailing twelve months, up 25.1% year over year.
Is Krystal Biotech, Inc. profitable?: Krystal Biotech, Inc. reported $225.0M in net income over the trailing twelve months, a 53.9% net margin.
What is Krystal Biotech, Inc.'s earnings per share?: Krystal Biotech, Inc.'s diluted EPS over the trailing twelve months is $7.48.
Where does Krystal Biotech, Inc.'s income statement data come from?: Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.